Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a prominent venture capital firm dedicated to investing in promising life science and healthcare companies, primarily within China and increasingly across global markets. Established with a strong foundation and a legacy connection to Eli Lilly and Company, LAV has evolved into an independent entity managing a series of successful funds. The firm's investment thesis centers on identifying and nurturing innovative technologies and business models that address significant unmet medical needs and improve healthcare outcomes. LAV leverages its deep industry expertise, extensive network, and strategic insights to support its portfolio companies from early-stage development through to commercialization.

LAV's investment strategy is broad yet focused, encompassing a wide array of sub-sectors within healthcare, including biopharmaceuticals, medical devices, diagnostics, and digital health solutions. They are known for their long-term perspective and their commitment to building enduring value in the companies they back. The firm actively partners with entrepreneurs, providing not just capital but also strategic guidance, operational support, and access to crucial resources. Their portfolio reflects a diverse range of companies, from novel drug discovery platforms to advanced medical technologies, all poised to make a significant impact on patient care.

Over the years, Lilly Asia Ventures has demonstrated substantial fundraising success and a robust investment pace. For instance, the firm successfully closed its LAV Fund VI in 2023, raising $650 million, following the equally successful $650 million close of LAV Fund V in 2021. These significant capital raises underscore the confidence investors place in LAV's ability to identify and scale leading healthcare innovations. With a strong track record of successful exits and a commitment to fostering groundbreaking advancements, LAV continues to play a pivotal role in shaping the future of the life sciences industry, particularly in the rapidly evolving Asian healthcare landscape.